
Operations Office

Telephone (507) 284-4852



Date: July 18, 2008

To: Primary Clinical Research Associates

From: Janis Wobschall
Research Protocol Specialist

Re: N0776, Phase II Trial of Avastin® in Combination with Sorafinib in Recurrent Glioblastoma Multiforme

The enclosed protocol is being prepared for activation and it is anticipated that it will activate within the next month.

You are encouraged to present this protocol to your IRB for review ASAP. We are only waiting for contract signatures and do not anticipate any additional changes prior to activation. This is a high priority study. It will provide recurrent glioblastoma patients access to bevacizumab, a promising anti glioma agent, free of charge.

We will notify you when the protocol officially activates. A forms packet will be included at that time.

Please note that this study was approved by the National Cancer Institute on February 2, 2008.

If you have any questions, please feel free to contact me.

Enclosure